Showing 2981-2990 of 7903 results for "".
Meibomian Gland Dysfunction After Cataract Surgery
https://crstoday.com/crst-issues/2022-aug/meibomian-gland-dysfunction-after-cataract-surgery/44802/Recent evidence indicates a shift in the standard of care.Global Perspectives
https://crstoday.com/crst-issues/2020-june/global-perspectives/44258/How eye care practitioners from around the world are dealing with the return to practice.Top Strategies for the Rock-Hard Nucleus
https://crstoday.com/crst-issues/mar-2021/top-strategies-for-the-rock-hard-nucleus/44419/A selection of preferred techniques and approaches to the management of a mature cataract.The Clareon® PanOptix® IOL: Setting the Standard in Trifocal Technology
https://crstoday.com/crst-supplements/the-clareon-panoptix-iol-setting-the-standard-in-trifocal-technology/the-clareon-panoptix-iol-setting-the-standard-in-trifocal-technology/45453/With optimized material design and ENLIGHTEN® technology, spectacle independence at all distances is possible.Global Update on CXL
https://crstoday.com/crst-issues/jan-2023/global-update-on-cxl/44896/Current status and developments on the horizon in different areas around the world.Common Postoperative Complications
https://crstoday.com/crst-issues/april-2021/common-postoperative-complications/44452/Key strategies for refractive misses, cystoid macular edema, high IOP, and pseudophakic bullous keratopathy.Immediate Sequential Bilateral Cataract Surgery: Yes or No?
https://crstoday.com/crst-issues/jan-2021/immediate-sequential-bilateral-cataract-surgery-yes-or-no/44385/Surgeons argue for and against use of this same-day surgical approach.What We Do Now Can Ease the Transition Back to ‘Normal’
https://crstoday.com/crst-issues/2020-june/what-we-do-now-can-ease-the-transition-back-to-normal/44255/US surgeons share their plans on how to ramp back up after the pandemic.News
https://crstoday.com/topics/general/news-6/43005/Inside a Hostile Takeover Battle
https://crstoday.com/topics/general/inside-a-hostile-takeover-battle/42635/Examining Valeant and its unprecedented bid for Allergan.